Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
Condition(s):Carcinoma, Transitional CellLast Updated:August 21, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Carcinoma, Transitional CellLast Updated:August 21, 2023Terminated
Condition(s):Glial Tumor of Brain; Diffuse Intrinsic Pontine Glioma; GliomaLast Updated:November 27, 2019Withdrawn
Condition(s):Cervical CancerLast Updated:December 28, 2023Recruiting
Condition(s):Diffuse Intrinsic Pontine GliomaLast Updated:March 4, 2024Active, not recruiting
Condition(s):Pancreatic CancerLast Updated:November 5, 2020Terminated
Condition(s):Malignant Neoplasm of Bone and Articular Cartilage; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Independent (Primary) Multiple Sites; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasm of Male Genital Organs; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma; Malignant Neoplasms of Thyroid and Other Endocrine Glands; Malignant Neoplasms of Urinary Tract; Melanoma and Other Malignant Neoplasms of SkinLast Updated:December 1, 2023Recruiting
Condition(s):Urinary Bladder CancerLast Updated:May 30, 2023Recruiting
Condition(s):Pancreatic CancerLast Updated:May 2, 2019Terminated
Condition(s):Pancreatic Cancer, Stage IB; Pancreatic Cancer, Stage IIA; Pancreatic Cancer, Stage IIB; Pancreatic Cancer Stage IIILast Updated:June 27, 2023Not yet recruiting
Condition(s):Metastatic Pancreatic Ductal AdenocarcinomaLast Updated:April 6, 2023Active, not recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.